Treatment and prevention of intraocular pressure increase after ophthalmic surgeries
https://doi.org/10.21516/2072-0076-2018-11-4-96-101
Abstract
The literary review is focused on reactive hypertension after eye surgeries. Possible causes of increased intraocular pressure are described. Methods of therapy and prevention of reactive hypertension after cataract phacoemulsification and intravitreal injections are analyzed. Literary data show an emphasis on the efficacy and safety of applying a fixed combination of brimonidine and timolol.
About the Authors
A. A. Antonov
Research Institute of Eye Diseases
Russian Federation
Russian Federation
Cand. Med. Sci., leading researcher
11A, Rossolimo St., Moscow, 119021, Russia
I. V. Kozlova
Research Institute of Eye Diseases
Russian Federation
Russian Federation
Cand. Med. Sci., senior researcher
11A, Rossolimo St., Moscow, 119021, Russia
D. V. Kosova
Research Institute of Eye Diseases
Russian Federation
Russian Federation
post-graduate student
11A, Rossolimo St., Moscow, 119021, Russia
References
1. Самойлов А.Я. Реактивная гипертензия глаза. Москва; 1926. Samoylov A.Y. Reactive ocular hypertension. Moscow; 1926 (in Russian).
2. Тахчиди Х.П., Иошин И.Э., Арутюнян И.А. и др. Особенности клиники и лечения больных с реактивной гипертензией после факоэмульсификации катаракты. Рефракционная хирургия и офтальмология. 2006; 2: 19–24. Takhchidi H.P., Ioshin I.E., Arutjunjan I.A., et al. Features of the clinic and treatment of patients with reactive hypertension after cataract phacoemulsification. Refractive surgery and ophthalmology. 2006; 2: 19–24 (in Russian).
3. Че нцова О.Б., Рябцева А.А., Можеренков В.П. и др. Прогнозирование развития гипертензии глаза после экстракции катаракты. Вестник офтальмологии. 1986; 2: 27–8. Chentsova O.B., Ryabtseva A.A., Mozherenkov V.P., et al. Forecasting the development of hypertension in the eye after cataract extraction. Vestnik oftal'mologii. 1986; 2: 27–8 (in Russian).
4. Федоров С.Н., Егорова Э.В., Иошин И.Э. и др. Механизм развития гипертензии в послеоперационном периоде при имплантации заднекамерных интраокулярных линз. Офтальмохирургия. 1991; 3: 6–10. Fedorov S.N., Egorova E.V., Ioshin I.E., et al. The mechanism of hypertension development in the postoperative period during implantation of posterior chamber intraocular lenses. Oftal'mokhirurgija. 1991; 3: 6–10 (in Russian).
5. Нестеров А.П., Бунин А.Я., Кацнельсон Л.А. Внутри глазное давление: физиология и патология. Москва: Наука; 1974. Nesterov A.P., Bunin A.Ya., Katsnel'son L.A. Intraocular pressure: physiology and pathology. Moscow: Nauka; 1974 (in Russian).
6. Сидоренко Е.И. Транзи торная гипертензия глаза после экстракции катаракты. Вестник офтальмологии. 1975; 3: 14–6. Sidorenko E.I. Transient hypertension of the eye after cataract extraction. Vestnik oftal'mologii. 1975; 3: 14–6 (in Russian).
7. David R., Tessler Z., Yagev R., et al. Persistently raised intraocular pressure following extracapsular cataract extraction. 1990; 74 (5): 272–4.
8. Ермакова В.Н. Влияние некоторых гипотензивных средств на простагландиновую глазную гипертензию. Вестник офтальмологии. 1981; 1: 11–2. Ermakova V.N. Effect of some antihypertensive agents on prostaglandin ocular hypertension. Vestnik oftal'mologii. 1981; 1: 11–2 (in Russian).
9. Fry L.L. Comparison of the postoperative intraocular pressure with Betagan, Betoptic, Timoptic, Iopidine, Diamox, Pilopine gel, and Miostat. J. of Cataract. Refract. Surg. 1992; 18 (1): 14–9.
10. Арутюнян Л.Л., Анисимов С.И., Анисимова С.Ю. и др. Гипотензивная эффективность ингибитора карбоангидразы дорзопта при послеоперационной офтальмогипертензии у пациентов с катарактой и первичной открытоугольной глаукомой. Российский офтальмологический журнал. 2013; 6 (4): 4–8. Arutyunyan L.L., Anisimov S.I., Anisimova S.Yu., et al. Hypotensive effectiveness of the dorsopt carboxohydrase inhibitor in postoperative ophthalmic hypertension in patients with cataract and primary open-angle glaucoma. Russian ophthalmological journal. 2013; 6 (4): 4–8 (in Russian).
11. Suzuki R., Tanaka K., Sagara T., et al. Reduction of intraocular pressure after phacoemulsification and aspiration with intraocular lens implantation. Ophthalmologica. 1994; 208 (5): 254–8. doi:10.1159/000310502
12. Vass C., Menapace R. Surgical strategies in patients with combined cataract and glaucoma. Curr Opin Ophthalmol. 2004; 15 (1): 61–6.
13. Pfeiffer N., Garcia-Feijoo J., Martinez-De-La-Casa J.M., et al. A randomized trial of a Schlemm's canal microstent with phacoemulsification for reducing intraocular pressure in openangle glaucoma. 2015; 122 (7): 1283–93.
14. Федоров С.Н., Егорова Э.В. Ошибки и осложнения при имплантации искусственного хрусталика. Москва; 1992. Fedorov S.N., Egorova E.V. Errors and complications of lens implantation. Moscow; 1992 (in Russian).
15. Hildebrand G.D., Wickremasinghe S.S., Tranos P.G., et al. Efficacy of anterior chamber decompression in controlling early intraocular pressure spikes after uneventful phacoemulsification. 2003; 29 (6): 1087–92.
16. Merkur A., Damji K.F., Mintsioulis G., et al. Intraocular pressure decrease after phacoemulsification in patients with pseudoexfoliation syndrome. 2001; 27 (4): 528–32.
17. Barron B.A., Busin M., Page C., et al. Comparison of the effects of Viscoat and Healon on postoperative intraocular pressure. 1985; 100 (3): 377–84.
18. Fogagnolo P., Centofanti M., Figus M., et al. Short-term changes in intraocular pressure after phacoemulsification in glaucoma patients. Ophthalmologica. 2012; 228 (3): 154–8. doi:10.1159/000337838
19. Ozkurt Y., Oral Y., Karacan O., et al. Comparison of the effects of Dorzolamide–Timolol fixed combination and Brimonidine on intraocular pressure after phacoemulsification surgery. 2008; 34 (1): 21–3.
20. Cetinkaya A., Akman A., Akova Y.A. Effect of topical brinzolamide 1 % and brimonidine 0,2 % on intraocular pressure after phacoemulsification. J. Cataract. Refract. Surg. 2004; 30 (8): 1736–41. doi:10.1016/j.jcrs.2003.12.050
21. Borazan M., Karalezli A., Akman A., et al. Effect of antiglaucoma agents on postoperative intraocular pressure after cataract surgery with Viscoat. J. Cataract. Refract. Surg. 2007; 33 (11): 1941–5. doi:10.1016/j.jcrs.2007.06.046
22. Dayanir V., Ozcura F., Kir E., et al. Medical control of intraocular pressure after phacoemulsification. J. Cataract. Refract. Surg. 2005; 31 (3): 484–8. doi:10.1016/j.jcrs.2004.07.024
23. Georgakopoulos C.D., Makri O.E., Plotas P., et al. Brinzolamidetimolol fixed combination for the prevention of intraocular pressure elevation after phacoemulsification. 2013; 41 (7): 662–7.
24. Kasetti S.R., Desai S.P., Sivakumar S., et al. Preventing intraocular pressure increase after phacoemulsification and the role of perioperative apraclonidine. 2002; 28 (12): 2177–80.
25. Pharmakakis N., Giannopoulos K., Stasinos S., et al. Effect of a fixed brimonidine–timolol combination on intraocular pressure after phacoemulsification. 2011; 37 (2): 279–83.
26. Sherwood M.B., Craven E.R., Chou C., et al. Twice-daily 0.2 % brimonidine 0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006; 124 (9): 1230–8. doi:10.1001/archopht.124.9.1230
27. Solish A.M., DeLucca P.T., Cassel D.A., et al. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma. 2004; 13 (2): 149–57.
28. Rainer G., Menapace R., Findl O., et al. Effect of topical brimonidine on intraocular pressure after small incision cataract surgery. J. Cataract. Refract. Surg. 2001; 27 (8): 1227–31.
29. Lai J.S., Chua J.K., Leung A.T., et al. Latanoprost versus timolol gel to prevent ocular hypertension after phacoemulsification and intraocular lens implantation. J. Cataract. Refract. Surg. 2000; 26 (3): 386–91.
30. Hoyng P.F., van Beek L.M. Pharmacological therapy for glaucoma: a review. Drugs. 2000; 59 (3): 411–34.
31. Золотарев А.В., Карлова Е.В., Николаева Г.А., Павлов Д.В. Морфология и функции увеосклерального оттока. Российский офтальмологический журнал. 2009; 2 (1): 35–9. Zolotarev A.V., Karlova E.V., Nikolaeva G.A., Pavlov D.V. Morphology and functions of uveoscleral outflow. Russian Ophthalmological Journal. 2009; 2 (1): 35–9 (in Russian).
32. Алексеев И.Б., Нам Ю.А., Григорьева М.С. Применение фиксированной комбинации бримонидина с тимололом для профилактики офтальмогипертензии после ультразвуковой факоэмульсификации неосложненной катаракты. Катарактальная и рефракционная хирургия. 2015; 15 (2): 11–5. Alekseev I.B., Nam Yu.A., Grigor’eva M.S. Brimonidine-tmolol fixed-dose combination prevents ocular hypertension after noncomplicated cataract phacoemulsification. Kataraktal’naya i refraktsionnaya khirurgiya. 2015; 15 (2): 11–5 (in Russian).
33. Kandarakis A., Soumplis V., Karampelas M., et al. Efficacy of brimonidine in preventing intraocular pressure spikes following phacoemulsification in glaucoma patients. Eur. J. Ophthalmol. 2010; 20 (6): 994–9.
34. Курышева Н.И. Бетаксолол в лечении первичн ой глаукомы. Г лаукома. 2006; 2: 73–7. Kurysheva N.I. Betaxolol in the treatment of primary glaucoma. Glaucoma. 2006; 2: 73–7 (in Russian).
35. Goni F.J. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur. J. Ophthalmol. 2005; 15 (5): 581–90. doi:10.5301/EJO.2008.4076
36. Higginbotham E.J., Feldman R., Stiles M., et al. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch. Ophthalmol. 2002; 120 (7): 915–22.
37. Strohmaier K., Snyder E., DuBiner H., et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology. 1998; 105 (10): 1936–44.
38. Diestelhorst M., Larsson L.J.B.j.o.o. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. 2004; 88 (2): 199–203.
39. Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr. Opin. Ophthalmol. 1996; 7 (2): 80–6.
40. Fraunfelder F.T., Sciubba J.J., Mathers W.D. The role of medications in causing dry eye. J Ophthalmol. 2012; 2012: 285851. doi:10.1155/2012/285851
41. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv. Ther. 2001; 18 (5): 205–15.
42. Lee A.J., McCluskey P. Fixed combination of topical brimonidine 0,2 % and timolol 0,5 % for glaucoma and uncontrolled intraocular pressure. Clin. Ophthalmol. 2008; 2 (3): 545–55.
43. Bakri S.J., Pulido J.S., McCannel C.A., et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond). 2009; 23 (1): 181–5. doi:10.1038/sj.eye.6702938
44. Kim J.E., Mantravadi A.V., Hur E.Y., et al. Short-term intraocular pressure changes immediately after intravitreal injections of antivascular endothelial growth factor agents. Am. J. Ophthalmol. 2008; 146 (6): 930–4; e1. doi:10.1016/j.ajo.2008.07.007
45. Farhood Q.K., Twfeeq S.M. Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients. Clin. Ophthalmol. 2014; 8: 599–604. doi:10.2147/OPTH.S58413
46. Hollands H., Wong J., Bruen R., et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can. J. Ophthalmol. 2007; 42 (6): 807–11. doi:10.3129/i07-172
47. Jager R.D., Aiello L.P., Patel S.C., et al. Risks of intravitreous injection: a comprehensive review. Retina. 2004; 24 (5): 676–98.
48. Yuksel-Elgin C., Elgin C. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection: a Meta-analysis. Int. J. Ophthalmol. 2016; 9 (1): 139–44. doi:10.18240/ijo.2016.01.23
49. Chang Y.C., Wu W.C. Elevation of intraocular pressure after intravitreal injection of triamcinolone acetonide in Taiwanese patients. Kaohsiung J. Med. Sci. 2008; 24 (2): 72–7. doi:10.1016/S1607-551X(08)70100-1
50. Jonas J.B., Degenring R.F., Kreissig I., et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005; 112 (4): 593–8. doi:10.1016/j.ophtha.2004.10.042
51. Adelman R.A., Zheng Q., Mayer H.R. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J. Ocul. Pharmacol. Ther. 2010; 26 (1): 105–10. doi:10.1089/jop.2009.0076
52. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006; 355 (14): 1419–31. doi:10.1056/NEJMoa054481
53. Brown D.M., Michels M., Kaiser P.K., et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular agerelated macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009; 116 (1): 57–65. doi:10.1016/j.
54. ophtha.2008.10.018
55. Quigley H.A., Anderson D.R. Distribution of axonal transport blockade by acute intraocular pressure elevation in the primate optic nerve head. Invest. Ophthalmol. Vis. Sci. 1977; 16 (7): 640–4.
56. Michelson G., Groh M.J., Langhans M. Perfusion of the juxtapapillary retina and optic nerve head in acute ocular hypertension. Ger. J. Ophthalmol. 1996; 5 (6): 315–21.
57. Theoulakis P.E., Lepidas J., Petropoulos I.K., et al. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin. Monbl. Augenheilkd. 2010; 227 (4): 280–4. doi:10.1055/s-0029-1245201
Review
For citations:
Antonov A.A., Kozlova I.V., Kosova D.V. Treatment and prevention of intraocular pressure increase after ophthalmic surgeries. Russian Ophthalmological Journal. 2018;11(4):96-102. (In Russ.) https://doi.org/10.21516/2072-0076-2018-11-4-96-101
Views:
1081
Email this article 